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Dear Editor 22 
The incidence of small intestinal neuroendocrine tumours (SINETs) is increasing and distant 23 
metastases are present at diagnosis in 70% of cases, the liver being the commonest site of 24 
metastasis (Yao et al. 2008). Despite this, our understanding of the mechanisms underlying 25 
metastatic progression of SINETs is currently limited and prior studies of the molecular 26 
biology of SINET liver metastases (LM) have been performed predominantly in small 27 
cohorts utilising candidate based techniques.   28 
SINETs have a low rate of mutations compared to most cancers.  Tthe most frequently 29 
mutated gene is CDKN1B (encoding p27, a cell cycle regulator); however mutations in this 30 
gene occur in only 8% of tumours and there is no characteristic mutational hotspot (Francis 31 
et al. 2013).  Furthermore, mutation of CDKN1B does not correlate with expression of p27 32 
(Crona et al. 2015).   We previously identified that SINETs are epigenetically dysregulated, 33 
and a panel of candidate driver epimutation genes has been identified (Karpathakis et al. 34 
2016). Therefore we postulated that metastatic progression in SINETs may also be 35 
epigenetically regulated.  Here we present findings from the largest molecular profiling study 36 
of SINET LM performed to date, integrating copy number variance (CNV), DNA 37 
methylation and RNA expression profiling to characterise the mechanisms underlying 38 
metastatic progression. 39 
Experimental details of DNA methylation, CNV and RNA expression profiling are as 40 
previously published (Karpathakis et al. 2016).  Patients provided informed consent for their 41 
tissue to be analysed in this study which was Research Ethics Committee approved (Ref: 42 
09/H0722/27). All cases were reviewed by two expert NET histopathologists (TVL/MN).   43 
Nucleic acids were extracted using standard methods (Qiagen:QIAamp DNA Mini kit, 44 
Roche:High Pure RNA Paraffin kit).  H&E stained sections were evaluated to ensure >80% 45 
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purity of tumour specimens. Methylation profiling was performed on the 46 
HumanMethylation450 BeadChip (HM450)(Illumina). Methylation data analysis was 47 
performed using ChAMP pipeline 48 
(https://www.bioconductor.org/packages/release/bioc/html/ChAMP.html).  Whole genome 49 
methylation profiling using Methylated DNA Immunoprecipitaion sequencing (MeDIP) was 50 
performed as previously described. MeDIP data was analysed using the custom pipeline 51 
MeDUSAv2.0 (https://www.ucl.ac.uk/cancer/research/department-cancer-biology/medical-52 
genomics-group/past-projects/medusa-project).   Gene expression analysis was performed on 53 
the Whole genome cDNA-mediated annealing, selection and ligation (DASL)(Illumina) 54 
assay.  Expression data was analysed using the ‘limma’ package in R 55 
(https://bioconductor.org/packages/release/bioc/html/limma.html).  Raw data from this study 56 
will be deposited in GEO (Accession number: XXXXXX) 57 
In summary, n=90 samples underwent array based DNA methylation analysis, n=26 samples 58 
underwent methylation specific immunoprecipitation followed by DNA sequencing, and 59 
n=49 underwent array based RNA expression analysis.  Of cases with relevant clinical data, 60 
93% had received no systemic treatment prior to specimen collection (27/29 cases). 61 
The CNV profile of SINET LM (n=20) mirrors that of primary tumours with the most 62 
frequent alteration of chr18 LOH seen in 79% of cases. A greater proportion of LM 63 
demonstrate amplification of chr20 (42%), deletion of chr19 (35%), whilst gain of 17q is 64 
found only in LM (21%). A trend of increased incidence of CNVs was seen in LM compared 65 
to SINET primary tumours (SINET primary: median 78megabasepair; LM: median 114mbp, 66 
p=0.08). 67 
Comparison of methylation profiles of SINET LM to that of primary SINETs identified 68 
29,263 methylation variable positions (MVPs) (adj p <0.05). Using a cut off of >30% 69 
Page 3 of 14
4 
 
difference in methylation between SINET primaries and LM, MVPs involving eight genes 70 
were identified (CLEC16A, HOXC4, HOXD4, IGF2AS, INS-IGF2, LDHA, RTN4RL1, 71 
SASH1). This suggests that the methylation profile of SINET primaries and metastases are 72 
broadly similar and that these epigenetic differences occurring in metastatic progression may 73 
be more subtle than those involved in primary tumorigenesis.  Global hypomethylation is 74 
noted in SINET primary tumours and occurs to an even greater extent in SINET LM (normal 75 
tissue methylation 0.628, primary 0.572, LM 0.515, p<0.001).   76 
Almost three thousand (n=2857) genes were significantly differentially expressed between 77 
LM and primary tumours. Using a > 3-fold alteration in gene expression, more genes were 78 
found to be upregulated (n=321) than downregulated (n=171) in LM.  KEGG pathway 79 
analysis (http://bioinfo.vanderbilt.edu/webgestalt/) of differentially expressed genes between 80 
LM and SINET primary identified significant enrichment of multiple cancer related pathways 81 
overexpressed in LM including PI3K signalling events, ErbB1 downstream signalling, 82 
PDGFRβ signalling pathway, and mTOR signalling pathway (adjusted p<0.001).  83 
Analysis of SINET LM identified progressive changes between SINET primaries and LM in 84 
DNA methylation and RNA expression in genes which had previously been identified in 85 
primary tumours when compared to normal tissue. This phenomenon was observed in a panel 86 
of 21 epigenetically dysregulated candidate driver genes which was previously identified 87 
(Karpathakis et al. 2016)(Table 1). 88 
LM demonstrated hyper/hypomethylation of all 21 genes in concordance with the pattern 89 
seen in SINET primaries when compared to normal tissue.  In 19 genes (90.5% of the panel) 90 
a trend for progressive hyper/hypomethylation was demonstrated in LM, of which 14 (66.6%) 91 
of the panel were significantly differentially methylated compared to the primary SINET. 92 
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All of the 21 genes included in the panel demonstrated over/under expression in LM in 93 
concordance with SINET primary tumours. In 15 genes (71.4% of panel) there was a 94 
progression of aberrant expression to a greater extent in LM than was demonstrated in SINET 95 
primaries (Figure 1, Table 1). 96 
Validation of SINET LM methylation status was performed in an independent cohort of 97 
seven LM profiled by methylated DNA immunoprecipitation sequencing (MeDIP-seq).  It 98 
was demonstrated that 20/21 (95.2%) genes exhibited concordant trends in methylation 99 
during progression from NSI to SI primary tumour to liver metastasis as was identified using 100 
HM450 profiling.  Statistically significant progressive aberrant methylation was 101 
demonstrated in 10/21 genes (47.6%). 102 
Validation of SINET LM expression status was performed utilising a publicly available 103 
dataset including three SINET primaries and three LM (GSE9576, Leja et al. 2009).  In total, 104 
10/21 (47.6%) of the candidate panel demonstrated a trend for progressive dysregulation in 105 
LM compared to primary tumours in keeping with the findings from the discovery dataset.  106 
The small number of cases included in this validation set limit the ability to confirm 107 
statistical significance. 108 
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Through integrated DNA methylation, CNV and RNA expression analysis we have identified 109 
progressive genomic derangements in SINET LM when compared to primary tumours.  110 
CNVs were seen more frequently in LM, in particular arm level amplifications, as previously 111 
reported (Hashemi et al. 2013).  Amplification of chromosome 17q was observed more 112 
frequently in LM than primaries in this cohort. This alteration has previously been described 113 
in both SINET and pancreatic NET primary tumours but this is the first time that increased 114 
frequency in LM has been identified.  Chromosome 17 harbours the proto-oncogene 115 
HER2/neu (17q11-21), amplification of which may be related to a more aggressive 116 
phenotype. 117 
The finding of progressive global hypomethylation in metastases compared to primary 118 
tumours is in keeping with previously published data (Verdugo et al. 2014).  A pattern of 119 
progressive aberrant methylation observed in our previously identified panel of 21 120 
epimutated genes in liver metastases, suggests that increasing epigenetic dysregulation may 121 
drive progression to metastasis. 122 
Transcriptome profiling demonstrated differential expression of 492 genes between LM and 123 
SINET primary tumours which may represent drivers of metastasis, including components of 124 
the PI3K/mTOR pathways.  Progressively dysregulated expression of the panel of candidate 125 
genes was demonstrated in liver metastases compared to primary tumours. This indicates 126 
escalating deregulation of aberrant expression of the genes and pathways associated 127 
development of SINET primary tumours occurs in association with metastatic progression.   128 
In total, 71.4% (15/21, expression) to 90.5% (19/21, methylation) of cases are affected by 129 
progressive dysregulation in association with metastasis. The gene encoding the gastric 130 
inhibitory polypeptide receptor (GIPR) is one of a panel of epigenetically dysregulated genes 131 
in SINETs which is significantly progressively hypermethylated in LM compared to primary 132 
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tumours.  This may represent a target for novel therapeutic agents in the management of 133 
SINETs, and has already been investigated as a target for novel imaging modalities (Sherman 134 
et al. 2013). 135 
In summary, integrated genomic analysis of a large cohort of SINET LM has identified novel 136 
molecular mechanisms associated with metastatic progression.  Epigenetic dysregulation of a 137 
panel of 21 candidate genes was identified in LM concordant with those found in primary 138 
SINET. Components of cancer related pathways including PI3K, mTOR and ErbB1 are 139 
overexpressed in liver metastases compared to normal tissue, which may be utilised as 140 
therapeutic targets.  Current clinical practice includes the use of agents targeting the mTOR 141 
pathway is based on evidence from the RADIANT trials of everolimus in pancreatic and 142 
SINETs (Yao et al. 2016).  The use of second line dual mTORC/PI3K inhibition for 143 
pancreatic NETs was not supported in a recently clinical trial (Fazio et al. 2016). Our data 144 
suggest the development of novel agents targeting epigenetic modifications in these pathways 145 
may hinder metastatic progression. 146 
Large scale alterations in the transcriptome of SINET LM compared to primary tumours have 147 
been identified, with more subtle alterations in the methylome.  This may indicate that small 148 
alterations in the epigenetic status of key genes are sufficient to drive metastatic progression, 149 
or that alternative mechanisms are also contributing to progression including for example 150 
histone modifications.  To date there have been no identified driver genetic mutations 151 
responsible for SINET development or progression.  The data presented in this manuscript 152 
suggest that epigenetic alterations are significant in this tumour type.  We believe that future 153 
research should be focused on further elucidating epigenetic mechanisms in the evolution of 154 
neuroendocrine tumours. 155 
 156 
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Figure and Table Legends 
Figure 1 Methylation and expression profile of SINET LM demonstrates progressive 
dysregulation compared to SINET primary tumours in a panel of genes 
Table 1 Methylation and expression profile of SINET LM demonstrates progressive 
dysregulation compared to SINET primary tumours in a panel of genes.  Normal small 
intestine (NSI), Small intestinal primary neuroendocrine tumour (SINET), Liver metastasis 
(LM). 
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  Median methylation Median Expression 
  NSI SINET LM Lm progressing trend? p (LM vs SINET) NSI SINET LM Lm progressing trend? p (LM vs SINET) 
Downregulated :               
CDX1 0.55 0.90 0.91 yes 0.48 5,481.4 1,503.0 570.8 yes 0.03 
FBP1 0.43 0.82 0.83 yes 0.58 10,896.0 2,193.1 2,937.5 no 0.54 
TMEM171 0.18 0.61 0.73 yes 0.11 3,632.7 519.6 201.9 yes 0.08 
C20orf54 0.34 0.64 0.60 no 0.64 2,320.5 577.0 176.7 yes 0.056 
GATA5 0.89 0.69 0.57 yes 0.006 658.2 64.0 65.8 no 0.96 
NGEF 0.89 0.72 0.60 yes 0.018 3,819.7 512.2 309.9 yes 0.23 
PNLIPRP2 0.77 0.47 0.33 yes 0.007 1,419.4 235.0 95.5 yes 0.34 
TRIM15 0.53 0.87 0.87 no 0.65 615.8 93.1 27.2 yes 0.009 
Upregulated :                     
PTPRN 0.38 0.11 0.07 yes 0.001 349.8 4,319.1 5,456.3 yes 0.1 
C3orf14 0.32 0.12 0.07 yes <0.001 212.4 1,016.7 1,803.9 yes 0.002 
CNTNAP5 0.26 0.09 0.08 yes 0.009 280.3 4,343.1 3,518.3 no 0.22 
DSCAM 0.50 0.15 0.08 yes <0.001 59.9 1,142.3 1,028.6 no 0.61 
GDAP1L1 0.38 0.08 0.05 yes 0.002 74.3 659.7 1,051.8 yes 0.07 
PCSK1 0.38 0.08 0.05 yes 0.001 217.9 2,420.4 2,911.0 yes 0.39 
PRLHR 0.44 0.13 0.06 yes <0.001 193.6 3,909.3 2,676.2 no 0.08 
SNTG1 0.28 0.07 0.04 yes <0.001 78.6 2,126.9 3,396.3 yes 0.003 
CELSR3 0.10 0.57 0.67 yes 0.11 2,029.6 7,869.0 9,442.6 yes 0.17 
GIPR 0.30 0.66 0.74 yes 0.034 248.1 1,900.0 2,283.6 yes 0.27 
KCNH6 0.07 0.36 0.48 yes 0.01 998.3 5,146.7 5,935.3 yes 0.35 
LMX1B 0.30 0.59 0.60 yes 0.99 286.8 3,503.9 1,979.4 no 0.034 
RUNDC3A 0.08 0.42 0.66 yes 0.02 454.2 3,966.4 5,677.8 yes 0.081 
Table 1
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Expression Methylation 
Downregulated Upregulated 
Upregulated Downregulated 
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